Avid Bioservices Inc (CDMO)

[biopharm]

Arranta CEO Mark Bamforth -

650 Pleasant St Watertown MA plans ...a little Avid expansion would fit nice or Ampersand would have some explaining to do on timeline of events and knowledge know how ....as Thermofisher will not just align themselves with Arranta without a plan of Biomarkers based on PS Targeting

So a strategic investment by Thermofisher? Rick Hancock BOD already told us that they considered expanding ....as they race to finish Arranta ...a little conflict? Hmm

Avid also told us they would consider investment by Thermofisher to supply equipment for what in return ??

Ampersand on thin ice as it looks to be clear conflicts in interest...unless they are failing to tell something ....yet

https://www.watertown-ma.gov/DocumentCenter/View/28054/05-Arranta-Site-Plan-Commitments---Sept-2019

_____


Ampersand Capital new CDMOs such as Arranta KNOW PS Targeting biomarkers led them to some gut..sy quick decisions to ramp up CDMOs because Avid Bioservices needs to expand...and quick
_____

China approves Alzheimer's drug, inviting fresh debate in field with few successes

Nov 4, 2019

...
...

Reducing neuroinflammation is one of the proposed mechanisms of action for oligomannate, which Green Valley says reconditions dysbiosis of gut microbiota as well as reduces amyloid protein deposition.

Links between bacteria in the gut and Alzheimer's have been proposed before, and researchers from Green Valley made the case for oligomannate's beneficial role via this pathway in a September 2019 paper published in Cell Research.

"There is no question that this data further supports the emerging idea that modulation of the gut microbiome via treatments such as GV-971 or other strategies should be further explored as novel strategies to slow the progression of AD," wrote researchers from Washington University School of Medicine in St. Louis, in an accompanying piece. GV-971 is another name used by Green Valley for oligomannate.
..
..


https://www.biopharmadive.com/news/china-alzheimers-drug-oligomannate-approval-green-valley/566540/

_______________


Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific

November 2, 2019

...
...

Arranta Bio announced the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific.

Formed in May 2019, Arrantas goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biotherapeutic products (LBPs) for microbiome pioneers by bacterial fermentation, isolation, drying and encapsulation.

Arrantas funding round was completed with sole institutional investor, Ampersand Capital Partners, company founders and colleagues, and a strategic investment from Thermo Fisher. Mark Bamforth, Arrantas Founder and CEO, said,

...
...
...
Over the last decade, there has been rapid acceleration in scientific understanding of the composition and functions of the gut microbiota. Arranta is proud to be building a business to support the supply needs of these innovators.
...
...

http://www.microbiometimes.com/arranta-bio-announces-82m-in-new-funding-and-a-strategic-partnership-with-thermo-fisher-scientific/